[go: up one dir, main page]

WO2009013846A1 - 前立腺肥大に伴う下部尿路症状の改善用医薬組成物 - Google Patents

前立腺肥大に伴う下部尿路症状の改善用医薬組成物 Download PDF

Info

Publication number
WO2009013846A1
WO2009013846A1 PCT/JP2007/074717 JP2007074717W WO2009013846A1 WO 2009013846 A1 WO2009013846 A1 WO 2009013846A1 JP 2007074717 W JP2007074717 W JP 2007074717W WO 2009013846 A1 WO2009013846 A1 WO 2009013846A1
Authority
WO
WIPO (PCT)
Prior art keywords
prostatomegaly
pharmaceutical composition
urinary tract
symptom associated
lower urinary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2007/074717
Other languages
English (en)
French (fr)
Inventor
Hidehiro Kakizaki
Masaki Yoshida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40281108&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2009013846(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Priority to CA2697137A priority Critical patent/CA2697137A1/en
Priority to EP07851069A priority patent/EP2172201A4/en
Priority to CN200780053847A priority patent/CN101754760A/zh
Priority to JP2009524370A priority patent/JPWO2009013846A1/ja
Publication of WO2009013846A1 publication Critical patent/WO2009013846A1/ja
Priority to US12/688,426 priority patent/US20100331361A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

　(R)-5-(2-{[2-(2-エトキシフェノキシ)エチル]アミノ}プロピル)-2-メトキシベンゼン-1-スルホンアミド（タムスロシン）又はその製薬学的に許容される塩、及び、(1S)-1-フェニル-1,2,3,4-テトラヒドロイソキノリン-2-カルボン酸 (3R)-キヌクリジン-3-イルエステル（ソリフェナシン）又はその製薬学的に許容される塩を有効成分とする医薬組成物、特に前立腺肥大に伴う下部尿路症状の改善用医薬組成物を提供する。また、前立腺肥大に伴う下部尿路症状の改善のためのタムスロシンまたはその製薬学的に許容される塩、及び、ソリフェナシンまたはその製薬学的に許容される塩の併用、及び併用療法を提供する。
PCT/JP2007/074717 2007-07-20 2007-12-21 前立腺肥大に伴う下部尿路症状の改善用医薬組成物 Ceased WO2009013846A1 (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA2697137A CA2697137A1 (en) 2007-07-20 2007-12-21 Pharmaceutical composition for amelioration of lower urinary tract symptoms associated with prostatomegaly
EP07851069A EP2172201A4 (en) 2007-07-20 2007-12-21 PHARMACEUTICAL COMPOSITION FOR THE REDUCTION OF LOWER HARNESS SYMPTOMS RELATED TO PROSTATE GAL
CN200780053847A CN101754760A (zh) 2007-07-20 2007-12-21 用以改善伴随着前列腺肥大的下尿路症状的药物组合物
JP2009524370A JPWO2009013846A1 (ja) 2007-07-20 2007-12-21 前立腺肥大に伴う下部尿路症状の改善用医薬組成物
US12/688,426 US20100331361A1 (en) 2007-07-20 2010-01-15 Pharmaceutical composition containing alpha-adrenergic receptor antagonist and an anti-muscarinic agent and method of improving lower urinary tract symptoms associated with prostatic hypertrophy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92999607P 2007-07-20 2007-07-20
US60/929996 2007-07-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/688,426 Continuation-In-Part US20100331361A1 (en) 2007-07-20 2010-01-15 Pharmaceutical composition containing alpha-adrenergic receptor antagonist and an anti-muscarinic agent and method of improving lower urinary tract symptoms associated with prostatic hypertrophy

Publications (1)

Publication Number Publication Date
WO2009013846A1 true WO2009013846A1 (ja) 2009-01-29

Family

ID=40281108

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/074717 Ceased WO2009013846A1 (ja) 2007-07-20 2007-12-21 前立腺肥大に伴う下部尿路症状の改善用医薬組成物

Country Status (8)

Country Link
US (1) US20100331361A1 (ja)
EP (1) EP2172201A4 (ja)
JP (1) JPWO2009013846A1 (ja)
KR (1) KR20100040294A (ja)
CN (1) CN101754760A (ja)
CA (1) CA2697137A1 (ja)
TW (1) TW200904424A (ja)
WO (1) WO2009013846A1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010090172A1 (ja) 2009-02-04 2010-08-12 アステラス製薬株式会社 経口投与用医薬組成物
JP2016508958A (ja) * 2012-10-15 2016-03-24 ケミン、インダストリーズ、インコーポレーテッドＫｅｍｉｎ Ｉｎｄｕｓｔｒｉｅｓ， Ｉｎｃ． 健康を促進するための緑茶抽出物と紅茶抽出物との混合物

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102743757A (zh) * 2012-07-09 2012-10-24 张家华 治疗膀胱流出道梗阻所致膀胱活动过度的药物
CN106562968B (zh) * 2015-10-13 2019-08-13 南京华威医药科技集团有限公司 包含盐酸坦洛辛和琥珀酸索利那新的药物组合物
US12274680B2 (en) 2022-09-13 2025-04-15 II George William Creasy Treatment of benign prostatic hypertrophy with capsinoids

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703063A (en) 1980-02-08 1987-10-27 Yamanouchi Pharmaceutical Co., Ltd. Sulfamoyl substituted phenethylamine derivatives and process of producing them
WO1996020194A1 (en) 1994-12-28 1996-07-04 Yamanouchi Pharmaceutical Co., Ltd. Novel quinuclidine derivatives and medicinal composition thereof
JP2001114679A (ja) * 1999-08-09 2001-04-24 Yamanouchi Pharmaceut Co Ltd 下部尿路症治療剤
WO2003103659A1 (ja) * 2002-06-07 2003-12-18 山之内製薬株式会社 過活動膀胱治療剤
WO2006090759A1 (ja) * 2005-02-25 2006-08-31 Astellas Pharma Inc. ソリフェナシン含有医薬

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2370501C (en) * 1999-08-09 2008-09-16 Yamanouchi Pharmaceutical Co., Ltd. Pharmaceutical composition for the therapy of lower urinary tract symptoms
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
WO2006038619A1 (ja) * 2004-10-06 2006-04-13 Kissei Pharmaceutical Co., Ltd. 前立腺肥大症に対する手術療法への移行予防用医薬組成物
EP2181707A1 (en) * 2008-11-04 2010-05-05 Astellas Ireland Co., Ltd. Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703063A (en) 1980-02-08 1987-10-27 Yamanouchi Pharmaceutical Co., Ltd. Sulfamoyl substituted phenethylamine derivatives and process of producing them
WO1996020194A1 (en) 1994-12-28 1996-07-04 Yamanouchi Pharmaceutical Co., Ltd. Novel quinuclidine derivatives and medicinal composition thereof
JP2001114679A (ja) * 1999-08-09 2001-04-24 Yamanouchi Pharmaceut Co Ltd 下部尿路症治療剤
WO2003103659A1 (ja) * 2002-06-07 2003-12-18 山之内製薬株式会社 過活動膀胱治療剤
WO2006090759A1 (ja) * 2005-02-25 2006-08-31 Astellas Pharma Inc. ソリフェナシン含有医薬

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FOLIA PHARMACOLOGICA JAPONICA, vol. 12, 2003, pages 331
See also references of EP2172201A4 *
THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol. 296, no. 19, 2006, pages 2319
THE JOURNAL OF UROLOGY, vol. 174, 2005, pages 1334

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010090172A1 (ja) 2009-02-04 2010-08-12 アステラス製薬株式会社 経口投与用医薬組成物
EP2394648A4 (en) * 2009-02-04 2012-08-29 Astellas Pharma Inc PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
JP5553026B2 (ja) * 2009-02-04 2014-07-16 アステラス製薬株式会社 経口投与用医薬組成物
US9198904B2 (en) 2009-02-04 2015-12-01 Astellas Pharma Inc. Pharmaceutical composition for oral administration
EP2394648B1 (en) 2009-02-04 2016-08-31 Astellas Pharma Inc. Pharmaceutical composition for oral administration
JP2016508958A (ja) * 2012-10-15 2016-03-24 ケミン、インダストリーズ、インコーポレーテッドＫｅｍｉｎ Ｉｎｄｕｓｔｒｉｅｓ， Ｉｎｃ． 健康を促進するための緑茶抽出物と紅茶抽出物との混合物

Also Published As

Publication number Publication date
CN101754760A (zh) 2010-06-23
TW200904424A (en) 2009-02-01
US20100331361A1 (en) 2010-12-30
EP2172201A4 (en) 2011-07-06
KR20100040294A (ko) 2010-04-19
CA2697137A1 (en) 2009-01-29
EP2172201A1 (en) 2010-04-07
JPWO2009013846A1 (ja) 2010-10-07

Similar Documents

Publication Publication Date Title
WO2009057685A1 (ja) 過活動膀胱治療用医薬組成物
WO2008088030A1 (ja) 血栓もしくは塞栓に関連する疾患の予防又は治療用組成物
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
WO2007087431A3 (en) Sublingual fentanyl spray
WO2007126964A3 (en) Kinase inhibitors
WO2010088000A3 (en) Antifibrotic compounds and uses thereof
WO2007149283A3 (en) Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload
EP2210606A3 (en) Compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases
HK1208803A1 (en) Crystalline forms of a bruton's tyrosine kinase inhibitor
WO2011119857A3 (en) Intravascular tissue disruption
WO2007087068A3 (en) Inhibitors of tyrosine kinases and uses thereof
WO2008011335A3 (en) Metal binding compounds, metal binding compositions, and their uses
NZ593467A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
WO2009013846A1 (ja) 前立腺肥大に伴う下部尿路症状の改善用医薬組成物
IL188438A (en) A heterocyclic active drug with five benzoposes, or a pharmaceutically acceptable salt and aster salts product, as well as compounds containing them and their use as @catol - o @ - @ of @ enzyme @ dead G iltransferase @@ comtI
HK1202448A1 (en) Topical formulation for administering a compound
EP1902715A3 (en) Use of paliperidone for the treatment of psychiatric patients with reduced hepatic function
WO2007025005A3 (en) Sustained release formulations of nalbuphine
RU2004135563A (ru) Лекарственное средство для лечения повышенной активности мочевого пузыря
WO2006017188A3 (en) Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
WO2009103476A8 (en) Antitumoral agents with a benzophenanthridine structure and formulations containing them
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
WO2008061671A3 (en) Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels
WO2007134085A3 (en) Isothiazolidines useful in the treatment of ocular hypertensive conditions
WO2014047288A3 (en) Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780053847.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07851069

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009524370

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20107001264

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2697137

Country of ref document: CA

Ref document number: 2007851069

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 382/CHENP/2010

Country of ref document: IN

Ref document number: MX/A/2010/000805

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE